X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate invIOs’ small molecule INV501 that can selectively enhance anti-tumor immune responses, as a potential treatment for glioblastoma.
Lead Product(s): INV501
Therapeutic Area: Oncology Product Name: INV501
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Invios
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 09, 2023
Details:
Anktiva™ (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex and which is investigated for advanced Head-and-Neck Cancer Patients.
Lead Product(s): Cytokine Induced Memory-Like Natural Killer Cell,Nogapendekin alfa Inbakicept
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: ImmunityBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., to develop anti-MUC1-C antibodies to selectively deliver Hillstream’s Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis.
Lead Product(s): HSB-1216
Therapeutic Area: Oncology Product Name: HSB-1216
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Hillstream BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 31, 2023
Details:
RRx-001 leads EpicentRx's CyNRGY platform as a first-in-class investigational treatment sourced from an exclusively licensed portfolio of aerospace-derived small molecules.
Lead Product(s): RRx-001,Cisplatin
Therapeutic Area: Gastroenterology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: EpicentRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
BHV-1100 targets the destruction of CD38-expressing cells in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immune globulin (Ig) in multiple myeloma patients undergoing autologous stem cell transplant.
Lead Product(s): KP1237,Autologous Cytokine Induced Memory-Like NK Cell
Therapeutic Area: Oncology Product Name: BHV-1100
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Biohaven Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Details:
The collaboration is designed to further investigate nirogacestat, SpringWorks’ investigational gamma-secretase inhibitor (GSI), with anti-B-cell maturation antigen (BCMA) agents in a variety of preclinical multiple myeloma models.
Lead Product(s): Nirogacestat,Anti-B-cell Maturation Antigen
Therapeutic Area: Oncology Product Name: PF-03084014
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SpringWorks Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 30, 2021
Details:
Funding will enable a wide range of ambitious work in two main areas of pancreatic cancer research: early detection and prevention, and precision medicine and biology.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Hale Family Center for Pancreatic Cancer Research
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 11, 2021
Details:
Through the newly announced EAP, the six clinical centers of excellence participating in the Phase 3 NurOwn® trial will each have the opportunity to treat ALS patients who completed the trial.
Lead Product(s): Autologous MSC-NTF cells
Therapeutic Area: Neurology Product Name: NurOwn
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: BrainStorm Cell Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
In the current trial, dubbed ZUMA-5, investigators administered axi-cel to 146 patients with follicular lymphoma or marginal zone lymphoma-two slow-growing forms of non-Hodgkin leukemia-at multiple U.S. medical centers.
Lead Product(s): Axicabtagene Ciloleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Yescarta
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
Details:
The collaboration aims at investigating the use of Kazia’s new drug, paxalisib (formerly GDC-0084), in primary central nervous system (CNS) lymphoma, a potential new indication for the drug. DFCI will initiate an open-label phase II clinical trial of paxalisib in PCNSL.
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kazia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
